Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Dietary changes may help alleviate celiac disease, says study

New research published in the Journal of Leukocyte Biology suggests that striking a balance of intestinal microbiota could play a role in early stages of celiac disease-related immune responses

30 Apr 2010

Depomed attributes 56% increase in first-quarter revenue to $5.8M increase in Glumetza product sales

Depomed, Inc. today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

Improved management practices can reduce annual costs from diabetes-related complications

Milliman Inc., a premier global consulting and actuarial firm, today released an analysis detailing the economic burden of type 2 diabetes on major healthcare payers and quantifying the savings that could result from better patient management practices.

29 Apr 2010

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.

29 Apr 2010

Many Americans aren't taking necessary steps to protect against diabetes: Study

Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.

28 Apr 2010

Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch

“Besides our ongoing partnership discussions, we will primarily focus on completing the Phase III studies and prepare for market launch of Diamyd®.”

28 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010

Second quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010

28 Apr 2010

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

DRCR Network study finds new treatment more effective

28 Apr 2010

Better vision ahead for many diabetic retinopathy patients

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

PPD confirms Japanese approval for Takeda's NESINA NDA

PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.

27 Apr 2010

Bayer Diabetes Care launches DIDGET blood glucose monitoring system in the US

Bayer Diabetes Care today announced the introduction of the DIDGET™ blood glucose monitoring system in the United States. The DIDGET meter is unique because it is the only blood glucose meter that connects directly to Nintendo DS™ and DS Lite gaming systems to help kids manage a lifelong disease by rewarding them for building consistent testing habits and meeting personalized blood glucose target ranges. Bayer's DIDGET meter is now available for purchase in the U.S. through CVS.com, Drugstore.com and Walgreens.com.

26 Apr 2010

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

Scientists at the University of Michigan Health System are teasing out clues to the effect of grapes in reducing risk factors related to cardiovascular disease and metabolic syndrome. The effect is thought to be due to phytochemicals -- naturally occurring antioxidants - that grapes contain.

26 Apr 2010

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Cigarette smoking is a major cause of illness and death worldwide. But it is a complex behavior, and how much people smoke, how hard they find it to quit, and the impact of long-term smoking on health varies greatly among individuals. A substantial portion of this variability is genetic. Two years ago, deCODE discovered the first common, single-letter variation in the sequence of the human genome, on chromosome 15q25, associated with nicotine addiction and risk of lung cancer.

26 Apr 2010

Highlights from AACE 19th Annual Meeting and Clinical Congress

today's highlights from the AACE Annual Meeting & Clinical Congress in Boston

24 Apr 2010

Study finds AFREZZA comparable to standard of care insulin therapy

Pulmonary function test results (PFTs) in patients treated with AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, at follow-up measurements were similar to PFT results observed in patients receiving standard antidiabetic therapy, according to data presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #267).

24 Apr 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Dietary changes may help alleviate celiac disease, says study

Depomed attributes 56% increase in first-quarter revenue to $5.8M increase in Glumetza product sales

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Improved management practices can reduce annual costs from diabetes-related complications

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Many Americans aren't taking necessary steps to protect against diabetes: Study

Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

DRCR Network study finds new treatment more effective

Better vision ahead for many diabetic retinopathy patients

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

PPD confirms Japanese approval for Takeda's NESINA NDA

Bayer Diabetes Care launches DIDGET blood glucose monitoring system in the US

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Highlights from AACE 19th Annual Meeting and Clinical Congress

Study finds AFREZZA comparable to standard of care insulin therapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in